JP2020533415A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533415A5
JP2020533415A5 JP2020536720A JP2020536720A JP2020533415A5 JP 2020533415 A5 JP2020533415 A5 JP 2020533415A5 JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020536720 A JP2020536720 A JP 2020536720A JP 2020533415 A5 JP2020533415 A5 JP 2020533415A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
acceptable salt
antidepressants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020536720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050339 external-priority patent/WO2019055369A1/en
Publication of JP2020533415A publication Critical patent/JP2020533415A/ja
Publication of JP2020533415A5 publication Critical patent/JP2020533415A5/ja
Pending legal-status Critical Current

Links

JP2020536720A 2017-09-12 2018-09-11 ナルコレプシーの処置におけるガボキサドールの使用 Pending JP2020533415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557412P 2017-09-12 2017-09-12
US62/557,412 2017-09-12
PCT/US2018/050339 WO2019055369A1 (en) 2017-09-12 2018-09-11 USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA

Publications (2)

Publication Number Publication Date
JP2020533415A JP2020533415A (ja) 2020-11-19
JP2020533415A5 true JP2020533415A5 (OSRAM) 2021-10-21

Family

ID=65630168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020536720A Pending JP2020533415A (ja) 2017-09-12 2018-09-11 ナルコレプシーの処置におけるガボキサドールの使用

Country Status (10)

Country Link
US (2) US20190076409A1 (OSRAM)
EP (1) EP3661507A4 (OSRAM)
JP (1) JP2020533415A (OSRAM)
KR (1) KR20200053570A (OSRAM)
CN (1) CN111328282A (OSRAM)
AU (1) AU2018331326A1 (OSRAM)
CA (1) CA3075478A1 (OSRAM)
IL (1) IL272962A (OSRAM)
MX (1) MX2020002741A (OSRAM)
WO (1) WO2019055369A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533415A (ja) * 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ナルコレプシーの処置におけるガボキサドールの使用
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020259787A1 (en) 2019-06-28 2020-12-30 University Of Copenhagen Treatment of cns disorders with sleep disturbances
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
US9480695B2 (en) * 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CN109414435A (zh) * 2016-05-26 2019-03-01 奥维德医疗公司 使用哌苯甲醇治疗行为综合征的方法
JP2020533415A (ja) * 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ナルコレプシーの処置におけるガボキサドールの使用

Similar Documents

Publication Publication Date Title
Stiskal et al. Neonatal paroxetine withdrawal syndrome
EP3970712A2 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
JP2006509751A5 (OSRAM)
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
AU2010211491B2 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
JP2016506933A5 (OSRAM)
CA2905457A1 (en) Treatment of cataplexy
JP2005523334A5 (OSRAM)
JP2025508406A5 (OSRAM)
RU2012152922A (ru) Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов
CA2485736A1 (en) Methods of treating gastrointestinal and genitourinary pain disorders using venlafaxine and derivatives
JP2012036212A5 (OSRAM)
TW200835477A (en) Methods for treating depression
JP2009542819A5 (OSRAM)
TWI409061B (zh) 莫達非尼於縮短抗抑鬱劑效果的開始時間的用途
JP2009542820A5 (OSRAM)
JP2025504984A5 (OSRAM)
JP2011516604A (ja) 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用
DK2533774T3 (en) USE OF AGOMELATIN FOR THE PREPARATION OF MEDICINALS FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE CONDITION (OCD)
RU2009101146A (ru) Лечение ожирения антагонистами мускаринового рецептора м1
Shao et al. Discovery of N-methyl-1-(1-phenylcyclohexyl) methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor
RU2019123563A (ru) Новые комбинации антагонистов н3-рецепторов и ингибиторов обратного захвата норадреналина и их терапевтическое применение
JP2025500344A5 (OSRAM)
MX2009001219A (es) Composicion farmaceutica que contiene en combinacion saredutant y un inhibidor selectivo de recaptacion de serotonina o un inhibidor de recaptacion de serotonina/norepinefrina.
Vasile et al. P. 2. c. 002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus